Caplin Point Laboratories
- P/E
- 27.60
Key Fundamentals
SmallcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 24.20%
- Debt to Equity
- 0.07
- EPS (TTM)
- ₹87.53
- Book Value
- ₹443.33
- Market Cap
- —
- P/E (TTM)
- 27.60
- P/B
- 5.45
- ROE
- 20.90%
- Dividend Yield
- 0.34%
- EBITDA
- ₹876 Cr
- 52W High
- ₹2,990.00
- 52W Low
- ₹1,500.30
- Day Range
- ₹2,353.10 – ₹2,425.10
- Volume
- 57,976
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Caplin Point Laboratories (this company) | ₹2,416.10 | 27.60 | ₹17,984 Cr | 5.45 | 0.34% | 20.90% | 24.20% | ₹2,287 Cr | ₹678 Cr |
| Median 8 companies | ₹2,048.60 | 37.20 | ₹1,25,337 Cr | 5.11 | 0.46% | 17.40% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 65
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 65
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 46
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 81
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 56
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 43
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is almost debt free.
- Company has delivered good profit growth of 21.4% CAGR over last 5 years
- Company's median sales growth is 19.9% of last 10 years
No weaknesses listed
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 6 | 5 | 8 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Neutral
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 49.19
- Neutral
- MACD (12,26,9)
- −61.38
- Bullish
- SMA (50)
- 2,558.09
- Bearish
- SMA (200)
- 2,170.73
- Bullish
As of
Analyst Rating
2 of 2 analysts rate Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | Irregular period |
|---|---|
| 5Y | +15.57% |
| 3Y | +14.24% |
| 1Y | +12.91% |
| TTM | +15.04% |
Net profit
| 10Y | Irregular period |
|---|---|
| 5Y | +20.96% |
| 3Y | +19.91% |
| 1Y | +20.15% |
| TTM | +19.58% |
Operating cash flow
| 10Y | Irregular period |
|---|---|
| 5Y | +14.22% |
| 3Y | +24.50% |
| 1Y | +21.06% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | Irregular period |
|---|---|
| 5Y | +3.97 pp |
| 3Y | +4.85 pp |
| 1Y | +1.37 pp |
| TTM | +0.96 pp |
Revenue by year
| Mar 2017 | ₹402 Cr |
|---|---|
| Mar 2018 | ₹540 Cr |
| Mar 2019 | ₹649 Cr |
| Mar 2020 | ₹863 Cr |
| Mar 2021 | ₹1,061 Cr |
| Mar 2022 | ₹1,269 Cr |
| Mar 2023 | ₹1,467 Cr |
| Mar 2024 | ₹1,694 Cr |
| Mar 2025 | ₹1,937 Cr |
| Mar 2026 | ₹2,187 Cr |
Net profit by year
| Mar 2017 | ₹96.00 Cr |
|---|---|
| Mar 2018 | ₹145 Cr |
| Mar 2019 | ₹177 Cr |
| Mar 2020 | ₹215 Cr |
| Mar 2021 | ₹251 Cr |
| Mar 2022 | ₹308 Cr |
| Mar 2023 | ₹377 Cr |
| Mar 2024 | ₹461 Cr |
| Mar 2025 | ₹541 Cr |
| Mar 2026 | ₹650 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Caplin Point Laboratories trades at a PE of 27.01 and market cap of ₹17,940 Cr as of 2026-11-03, with a near debt-free balance sheet (debt-to-equity of 0.07) and a 10-year compounded profit growth of 30%. The stock sits about 21% below its 52-week high of ₹2,990 while being 58% above its 52-week low of ₹1,500.30, reflecting meaningful volatility within the period.
- Virtually debt-free with a debt-to-equity ratio of just 0.07, giving the company significant financial flexibility and resilience against interest rate cycles.
- Exceptional long-term profit compounding at 30% CAGR over 10 years, indicating a durable and scalable business model in the pharmaceutical space.
- 10-year compounded sales growth of 25% and a median sales growth of 19.9% over the last decade point to consistent top-line expansion.
- ROCE of 21.96% signals efficient capital deployment, well above the cost of capital for most Indian pharmaceutical companies.
- ROE has remained robust at 22-25% across 3-year, 5-year and 10-year periods, with the latest year at 21%, demonstrating steady returns on shareholder equity.
- 5-year compounded profit growth of 21% and 5-year sales growth of 16% show the company has maintained healthy profitability even in recent years beyond the long-term trend.
- Stock CAGR of 30% over 3 years has significantly outpaced the broader market, reflecting investor recognition of the company's growth trajectory.
- TTM sales growth of 15% and TTM profit growth of 18% indicate that the business continues to grow at a healthy pace in the most recent period.
- PE of 27.01 is elevated relative to the TTM EPS growth of 18%, implying a PEG ratio above 1.5 and suggesting the stock may already price in near-term growth.
- The stock is trading 21% below its 52-week high of ₹2,990, indicating recent selling pressure or weakening sentiment at higher valuations.
- Dividend yield of just 0.34% provides negligible income return, making the stock reliant almost entirely on capital appreciation for shareholder returns.
- Sales growth has decelerated from the 10-year CAGR of 25% to the 3-year CAGR of 14% and TTM of 15%, suggesting the top-line growth rate may be plateauing.
- Profit growth has similarly moderated from 30% over 10 years to 19% over 3 years and 18% TTM, raising questions about whether the company can sustain historically high growth rates.
- ROE has declined from the 10-year average of 25% to 21% in the last year, a trend that, if continued, could weigh on the premium valuation multiples.
- With a market cap of ₹17,940 Cr, the company is in mid-cap territory where liquidity risk and volatility can be amplified during broader market corrections, as evidenced by the wide 52-week range of ₹1,500-₹2,990.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Limited recent news flow for Caplin Point Laboratories. The only development is a routine AGM with standard board-level appointments, signaling management continuity. No material headwinds or catalysts are visible from current coverage, so the near-term outlook hinges on upcoming quarterly results and any regulatory or pipeline updates.
- AGM with key director appointments Sep 25
Caplin Point held its 35th AGM on September 25, 2026, re-appointing Dr. Sridhar Ganesan as MD and appointing Mr. D. Muralidharan as Whole-Time Director.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 |
| Expenses | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 |
| Operating Profit | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 |
| OPM % | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% | 35% |
| Other Income | 12 | 20.43 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 |
| PBT | 127 | 146 | 145 | 146 | 154 | 169 | 177 | 177 | 184 | 201 | 204 | 213 | 225 |
| Tax % | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% |
| Net Profit | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 |
| EPS (₹) | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.1 | 20.32 | 21.56 | 22.38 | 23.27 |
Profit & Loss
₹ Cr| Particulars | Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 | 2,287 |
| Expenses | 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,142 | 1,287 | 1,422 | 1,491 |
| Operating Profit | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 765 | 797 |
| OPM % | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 34% | 35% | 35% |
| Other Income | 3 | 4 | 10 | 13 | 19 | 41 | 23 | 38 | 55 | 66 | 92 | 111 | 126 |
| Interest | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 73 | 78 |
| PBT | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 803 | 844 |
| Tax % | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | 18% | 20% | 19% | — |
| Net Profit | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 | 678 |
| EPS (₹) | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 | 87.53 |
| Div. Payout % | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% | 8% | 9% | — |
Balance Sheet
₹ Cr| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 78 | 113 | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,084 | 2,619 | 3,355 |
| Borrowings | 2 | 2 | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 221 |
| Other Liabilities | 134 | 137 | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 446 |
| Total Liabilities | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,038 |
| Fixed Assets | 113 | 144 | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 580 |
| CWIP | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 234 |
| Investments | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 859 |
| Other Assets | 85 | 122 | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,410 | 1,753 | 1,928 | 2,365 |
| Total Assets | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,038 |
Cash Flow
₹ Cr| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 50 | 42 | 68 | 66 | 83 | 45 | 269 | 337 | 271 | 318 | 432 | 523 |
| Investing | −23 | −6 | −36 | −69 | −100 | −54 | −30 | −377 | −216 | −319 | −333 | −582 |
| Financing | −9 | −14 | −7 | −12 | 90 | 80 | −24 | −41 | −28 | −38 | −38 | −46 |
| Net Cash Flow | 19 | 23 | 25 | −14 | 73 | 70 | 215 | −81 | 27 | −39 | 61 | −105 |
| Free Cash Flow | 24 | 34 | 43 | 18 | 18 | −32 | 195 | 246 | 78 | 173 | 241 | 275 |
| CFO/EBITDA | 103 | 92 | 73 | 53 | 54 | 38 | 102 | 106 | 81 | 77 | 86 | 87 |
Ratios
| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8 | 12 | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 | 138 |
| Inventory Days | 37 | 57 | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 | 181 |
| Days Payable | 112 | 168 | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 116 | 103 | 125 |
| Cash Conversion Cycle | −67 | −99 | −81 | −16 | 61 | 251 | 166 | 138 | 173 | 184 | 175 | 194 |
| Working Capital Days | −128 | −114 | −29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 174 | 199 |
| ROCE % | 68% | 62% | 68% | 63% | 45% | 33% | 28% | 28% | 26% | 26% | 26% | 24% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Caplin Point Laboratories insights
70 extracted metrics across FY12–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- Q1 FY26 concall · Aug 2025Transcript PPT Recording
- 12 Aug 2026
- General announcements 2 Nov 2026
- General announcements 7 Oct 2026
Frequently Asked Questions about Caplin Point Laboratories
What does Caplin Point Laboratories Ltd do?
Where is Caplin Point Laboratories Ltd (CAPLIPOINT) listed?
Which sector does Caplin Point Laboratories Ltd belong to?
What is the PE ratio of Caplin Point Laboratories Ltd?
What is the 52-week high and low of Caplin Point Laboratories Ltd?
Does Caplin Point Laboratories Ltd pay dividends?
What is the Return on Equity (ROE) of Caplin Point Laboratories Ltd?
Company Information
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CAPLIPOINT.md for Caplin Point Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.